+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study



Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study



European Urology 20(2): 89-92



From September 1984 to December 1988, 28 consecutive patients with metastatic urothelial cancer entered a randomized study to compare 4 courses of modified methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) to 4 courses of methotrexate followed by folinic acid rescue and cisplatin (MP). Non-responders or relapsing patients were to be crossed to the other therapy. Hematological toxicity was more frequent (85%), but less severe, in patients treated with M-VAC than in patients treated with MP (21%, with 1 septic death). Complete plus partial remissions were achieved in 10 (71.4%) of 14 patients treated with M-VAC and in 6 (50%) of the 12 evaluable patients treated with MP. The 20% difference lay only on complete remissions, which were 8.3% in the MP versus 28.5% in the M-VAC group. At cross-over, however, only 1 of 5 patients resistant to MP responded to M-VAC, while 3 of 5 patients resistant to M-VAC responded to MP. It seems that M-VAC should be considered as the first-line therapy of choice in metastatic urothelial cancer, while MP, or high-dose methotrexate, could be considered for salvage.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 007549667

Download citation: RISBibTeXText

PMID: 1752280


Related references

Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group. Japanese Journal of Clinical Oncology 28(8): 497-501, 1998

Methotrexate vinblastine adriamycin cisplatin m vac vs high dose methotrexate continuous infusion cisplatin hdmp in metastatic urothelial cancer. Journal of Urology 141(4 Part 2): 214A, 1989

Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. Urology 79(2): 384-390, 2012

Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). Journal of Clinical Oncology 23(22): 4963-4974, 2005

Efficacy of Dose-intensified Mec (Methotrexate, Epirubicin and Cisplatin) Chemotherapy for Advanced Urothelial Carcinoma: a Prospective Randomized Trial Comparing Mec and M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin). Japanese Journal of Clinical Oncology 28(8): 497-501, 1998

Adjuvant systemic chemotherapy with cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin for locally advanced bladder cancer Results of a randomized, multicenter phase III study in Germany. Journal of Urology 169(4 Suppl.): 337, 2003

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in Urology 2013: 317190, 2013

Combination chemotherapy of advanced urothelial cancer with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC). Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 79(9): 1510-1515, 1988

Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer. Hinyokika Kiyo. Acta Urologica Japonica 40(4): 303-307, 1994

Clinical evaluation of M-VAC chemotherapy (methotrexate, vinblastine, adriamycin and cisplatin) for advanced urothelial cancer. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 80(3): 321-328, 1989

Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 82(10): 1627-1636, 1991

Combination chemotherapy of methotrexate vinblastine adriamycin and cisplatin m vac regimen for advanced urothelial cancer an arterial infusion of locally advanced urothelial cancer. Nishinihon Journal of Urology 50(5): 1579-1583, 1988

Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer. Hinyokika Kiyo. Acta Urologica Japonica 34(8): 1371-1375, 1988

Experience of combination chemotherapy consisting of methotrexate vinblastine adriamycin and cisplatin m vac for advanced urothelial cancer. Acta Urologica Japonica 34(8): 1371-1375, 1988

Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin for locally advanced bladder cancer Results of a randomised, multicenter phase III study in Germany. European Urology Suppl.s 2(1): 126, 2003